Guidance

Hepatitis A/Typhoid vaccine: patient group direction

PGD template to support the provision of hepatitis A/typhoid (HepA/Typhoid) vaccine, for travel or in accordance with PHE hepatitis A temporary recommendations.

Documents

Hepatitis A/Typhoid vaccine: patient group direction

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of HepA/Typhoid vaccine to individuals considered at risk of exposure to Salmonella enterica serovar typhi, (S. typhi) and/or hepatitis A virus, in accordance with recommendations from the National Travel Health Network and Centre (NaTHNaC) or in accordance with PHE hepatitis A temporary recommendations.

It is valid from 1 March 2018 to 29 February 2020.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012).

Practitioners should follow local policy and procedures to access authorised PGD documents. This PGD template should be used with reference to current national guidance, Green Book, and Summary of Product Characteristics for the vaccine.

Published 23 February 2018